{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:09:40Z","timestamp":1787987380346,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early detection of atrial fibrillation (AF) enables initiation of anticoagulation and early rhythm control therapy to reduce stroke, cardiovascular death, and heart failure. In a cross-sectional, observational study, we aimed to identify a combination of circulating biomolecules reflecting different biological processes to detect prevalent AF in patients with cardiovascular conditions presenting to hospital. Twelve biomarkers identified by reviewing literature and patents were quantified on a high-precision, high-throughput platform in 1485 consecutive patients with cardiovascular conditions (median age 69\u00a0years [Q1, Q3 60, 78]; 60% male). Patients had either known AF (45%) or AF ruled out by 7-day ECG-monitoring. Logistic regression with backward elimination and a neural network approach considering 7 key clinical characteristics and 12 biomarker concentrations were applied to a randomly sampled discovery cohort (n\u2009=\u2009933) and validated in the remaining patients (n\u2009=\u2009552). In addition to age, sex, and body mass index (BMI), BMP10, ANGPT2, and FGF23 identified patients with prevalent AF (AUC 0.743 [95% CI 0.712, 0.775]). These circulating biomolecules represent distinct pathways associated with atrial cardiomyopathy and AF. Neural networks identified the same variables as the regression-based approach. The validation using regression yielded an AUC of 0.719 (95% CI 0.677, 0.762), corroborated using deep neural networks (AUC 0.784 [95% CI 0.745, 0.822]). Age, sex, BMI and three circulating biomolecules (BMP10, ANGPT2, FGF23) are associated with prevalent AF in unselected patients presenting to hospital. Findings should be externally validated. Results suggest that age and different disease processes approximated by these three biomolecules contribute to AF in patients. Our findings have the potential to improve screening programs for AF after external validation.<\/jats:p>","DOI":"10.1038\/s41598-023-42331-7","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T10:02:11Z","timestamp":1696500131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions"],"prefix":"10.1038","volume":"13","author":[{"given":"Winnie","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor R.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Guasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz F.","family":"Sinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Al-Taie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J. G. M.","family":"Crijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elton A. M. P.","family":"Dudink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane N.","family":"Hatem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"K\u00e4\u00e4b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Mont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Nehaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanish","family":"Purmah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeet S.","family":"Reyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Schotten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Sommerfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stef","family":"Zeemering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios V.","family":"Gkoutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Fabritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"42331_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46619\/joh.2020.1-1001","volume":"1","author":"G Hindricks","year":"2020","unstructured":"Hindricks, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 1, 1 (2020).","journal-title":"Eur. Heart J."},{"issue":"1","key":"42331_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January, C. T. et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart rhythm society. J. Am. Coll. Cardiol. 74(1), 104\u2013132 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"42331_CR3","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1161\/STROKEAHA.113.001884","volume":"44","author":"M Grond","year":"2013","unstructured":"Grond, M. et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: A prospective multicenter cohort study. Stroke 44(12), 3357\u20133364 (2013).","journal-title":"Stroke"},{"key":"42331_CR4","first-page":"1","volume":"1","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof, P. et al. Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med. 1, 1 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"42331_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.116.026693","volume":"135","author":"B Freedman","year":"2017","unstructured":"Freedman, B. et al. Screening for atrial fibrillation: A report of the AF-SCREEN international collaboration. Circulation 135(19), 1851\u20131867 (2017).","journal-title":"Circulation"},{"issue":"25","key":"42331_CR6","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1161\/CIRCULATIONAHA.114.014343","volume":"131","author":"E Svennberg","year":"2015","unstructured":"Svennberg, E. et al. Mass screening for untreated atrial fibrillation: The STROKESTOP study. Circulation 131(25), 2176\u20132184 (2015).","journal-title":"Circulation"},{"issue":"4","key":"42331_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/ehjdh\/ztac067","volume":"3","author":"L Fabritz","year":"2022","unstructured":"Fabritz, L. et al. Smartphone and wearable detected atrial arrhythmias in older adults: Results of a fully digital European Case finding study. Eur. Heart J. Digit. Health 3(4), 610\u2013625 (2022).","journal-title":"Eur. Heart J. Digit. Health"},{"issue":"9","key":"42331_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41591-022-01979-w","volume":"28","author":"KD Rizas","year":"2022","unstructured":"Rizas, K. D. et al. Smartphone-based screening for atrial fibrillation: A pragmatic randomized clinical trial. Nat. Med. 28(9), 1823\u20131830 (2022).","journal-title":"Nat. Med."},{"issue":"1","key":"42331_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/europace\/euz255","volume":"22","author":"K Kemp Gudmundsdottir","year":"2020","unstructured":"Kemp Gudmundsdottir, K. et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace 22(1), 24\u201332 (2020).","journal-title":"Europace"},{"issue":"2","key":"42331_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.007607","volume":"13","author":"L Staerk","year":"2020","unstructured":"Staerk, L. et al. Protein biomarkers and risk of atrial fibrillation: The FHS. Circ. Arrhythm. Electrophysiol. 13(2), e007607 (2020).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"10","key":"42331_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jacc.2010.02.066","volume":"56","author":"SC Marott","year":"2010","unstructured":"Marott, S. C. et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J. Am. Coll. Cardiol. 56(10), 789\u2013795 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"42331_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/eurheartj\/ehy815","volume":"40","author":"W Chua","year":"2019","unstructured":"Chua, W. et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur. Heart J. 40(16), 1268\u20131276 (2019).","journal-title":"Eur. Heart J."},{"issue":"5","key":"42331_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jamacardio.2016.1445","volume":"1","author":"R Mehta","year":"2016","unstructured":"Mehta, R. et al. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol. 1(5), 548\u2013556 (2016).","journal-title":"JAMA Cardiol."},{"issue":"2","key":"42331_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003405","volume":"18","author":"W Chua","year":"2021","unstructured":"Chua, W. et al. Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. PLoS Med. 18(2), e1003405 (2021).","journal-title":"PLoS Med."},{"issue":"4","key":"42331_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrcardio.2015.194","volume":"13","author":"L Fabritz","year":"2016","unstructured":"Fabritz, L. et al. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: A roadmap to underpin personalized prevention and treatment. Nat. Rev. Cardiol. 13(4), 230\u2013237 (2016).","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"42331_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/europace\/eux318","volume":"20","author":"D Kotecha","year":"2018","unstructured":"Kotecha, D. et al. Integrating new approaches to atrial fibrillation management: The 6th AFNET\/EHRA Consensus Conference. Europace 20(3), 395\u2013407 (2018).","journal-title":"Europace"},{"issue":"24","key":"42331_CR17","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1093\/eurheartj\/ehp235","volume":"30","author":"P Kirchhof","year":"2009","unstructured":"Kirchhof, P. et al. Early and comprehensive management of atrial fibrillation: Executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference \u201cresearch perspectives in AF\u201d. Eur. Heart J. 30(24), 2969\u20132977 (2009).","journal-title":"Eur. Heart J."},{"issue":"1","key":"42331_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12872-019-1105-4","volume":"19","author":"W Chua","year":"2019","unstructured":"Chua, W. et al. Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: A protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovasc. Disord. 19(1), 120 (2019).","journal-title":"BMC Cardiovasc. Disord."},{"issue":"9","key":"42331_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"42331_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/1467-9876.00155","volume":"48","author":"W Sauerbrei","year":"1999","unstructured":"Sauerbrei, W. The use of resampling methods to simplify regression models in medical statistics. J. R. Stat. Soc. Ser. C Appl. Stat. 48, 313\u2013329 (1999).","journal-title":"J. R. Stat. Soc. Ser. C Appl. Stat."},{"key":"42331_CR21","unstructured":"R Core Team, R: A language and environment for statistical computing. 2017, R Foundation for Statistical Computing: Vienna, Austria."},{"issue":"2","key":"42331_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.000102","volume":"2","author":"A Alonso","year":"2013","unstructured":"Alonso, A. et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: The CHARGE-AF consortium. J. Am. Heart Assoc. 2(2), e000102 (2013).","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"42331_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jchf.2013.02.004","volume":"1","author":"M Richards","year":"2013","unstructured":"Richards, M. et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: Results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail. 1(3), 192\u2013199 (2013).","journal-title":"JACC Heart Fail."},{"issue":"4","key":"42331_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022833","volume":"11","author":"PF Brady","year":"2022","unstructured":"Brady, P. F. et al. Interactions between atrial fibrillation and natriuretic peptide in predicting heart failure hospitalization or cardiovascular death. J. Am. Heart Assoc. 11(4), e022833 (2022).","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"42331_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/eurheartj\/ehac632","volume":"44","author":"Z Hijazi","year":"2023","unstructured":"Hijazi, Z. et al. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. Eur. Heart J. 44(3), 208\u2013218 (2023).","journal-title":"Eur. Heart J."},{"issue":"6","key":"42331_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028255","volume":"12","author":"E Hennings","year":"2023","unstructured":"Hennings, E. et al. Bone morphogenetic protein 10-A novel biomarker to predict adverse outcomes in patients with atrial fibrillation. J. Am. Heart Assoc. 12(6), e028255 (2023).","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"42331_CR27","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.hrthm.2016.05.028","volume":"14","author":"A Goette","year":"2017","unstructured":"Goette, A. et al. EHRA\/HRS\/APHRS\/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart Rhythm 14(1), e3\u2013e40 (2017).","journal-title":"Heart Rhythm"},{"issue":"3","key":"42331_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/europace\/euaa279","volume":"23","author":"L Fabritz","year":"2021","unstructured":"Fabritz, L. et al. Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: The 7th AFNET\/EHRA Consensus Conference. Europace 23(3), 329\u2013344 (2021).","journal-title":"Europace"},{"issue":"2","key":"42331_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrcardio.2015.156","volume":"13","author":"NW Morrell","year":"2016","unstructured":"Morrell, N. W. et al. Targeting BMP signalling in cardiovascular disease and anaemia. Nat. Rev. Cardiol. 13(2), 106\u2013120 (2016).","journal-title":"Nat. Rev. Cardiol."},{"issue":"16","key":"42331_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.139179","volume":"5","author":"JS Reyat","year":"2020","unstructured":"Reyat, J. S. et al. Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. JCI Insight 5(16), 1 (2020).","journal-title":"JCI Insight"},{"key":"42331_CR31","first-page":"1","volume":"1","author":"M Litvinukova","year":"2020","unstructured":"Litvinukova, M. et al. Cells of the adult human heart. Nature 1, 1 (2020).","journal-title":"Nature"},{"key":"42331_CR32","first-page":"1","volume":"1","author":"A Piek","year":"2020","unstructured":"Piek, A. et al. A combined bioinformatics, experimental and clinical approach to identify novel cardiac-specific heart failure biomarkers: Is Dickkopf-3 (DKK3) a possible candidate?. Eur. J. Heart Fail. 1, 1 (2020).","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"42331_CR33","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41598-022-05769-9","volume":"12","author":"PB Meyre","year":"2022","unstructured":"Meyre, P. B. et al. Biomarkers associated with rhythm status after cardioversion in patients with atrial fibrillation. Sci. Rep. 12(1), 1680 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"42331_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12872-021-02358-y","volume":"21","author":"L Staszewsky","year":"2021","unstructured":"Staszewsky, L. et al. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. BMC Cardiovasc. Disord. 21(1), 553 (2021).","journal-title":"BMC Cardiovasc. Disord."},{"issue":"5","key":"42331_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells8050471","volume":"8","author":"RG Akwii","year":"2019","unstructured":"Akwii, R. G. et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells 8(5), 1 (2019).","journal-title":"Cells"},{"issue":"11","key":"42331_CR36","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood-2003-10-3685","volume":"103","author":"U Fiedler","year":"2004","unstructured":"Fiedler, U. et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103(11), 4150\u20134156 (2004).","journal-title":"Blood"},{"issue":"5","key":"42331_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/07853890510037392","volume":"37","author":"B Freestone","year":"2005","unstructured":"Freestone, B. et al. Angiogenic factors in atrial fibrillation: A possible role in thrombogenesis?. Ann. Med. 37(5), 365\u2013372 (2005).","journal-title":"Ann. Med."},{"issue":"7","key":"42331_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016041","volume":"9","author":"JP Law","year":"2020","unstructured":"Law, J. P. et al. Clinical potential of targeting fibroblast growth Factor-23 and alphaKlotho in the treatment of uremic cardiomyopathy. J. Am. Heart. Assoc. 9(7), e016041 (2020).","journal-title":"J. Am. Heart. Assoc."},{"issue":"1","key":"42331_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/europace\/euac062","volume":"25","author":"RB Schnabel","year":"2023","unstructured":"Schnabel, R. B. et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: The 8th AFNET\/EHRA consensus conference. Europace 25(1), 6\u201327 (2023).","journal-title":"Europace"},{"key":"42331_CR40","first-page":"1","volume":"1","author":"P Kirchhof","year":"2023","unstructured":"Kirchhof, P. et al. Anticoagulation with Edoxaban in patients with atrial high-rate episodes. N. Engl. J. Med. 1, 1 (2023).","journal-title":"N. Engl. J. Med."},{"key":"42331_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ahj.2017.04.008","volume":"189","author":"RD Lopes","year":"2017","unstructured":"Lopes, R. D. et al. Rationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial. Am. Heart J. 189, 137\u2013145 (2017).","journal-title":"Am. Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42331-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:24:07Z","timestamp":1700490247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42331-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42331"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42331-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"24 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed the ICMJE uniform disclosure form at  and declare: LF has received institutional research grants and non-financial support from European Union, British Heart Foundation, Medical Research Council (UK), DFG,\u00a0German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK) and several biomedical companies. PKi has received additional support for research from the European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Heart Research, from several drug and device companies active in atrial fibrillation, honoraria from several such companies. PKi and LF are listed as inventors on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). PKa is an employee of Roche Diagnostics GmbH. AZ is an employee of Roche Diagnostics Intl. All other authors have reported no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16743"}}